表皮生长因子受体与多形性胶质母细胞瘤放疗抵抗  

Epidermal Growth Factor Receptor and Its Resistance to Radiaotherapy in Glioblastoma Multiforme

作　　者：宋海斌[1] 褚倩[1] 

机构地区：[1]华中科技大学同济医学院附属同济医院,湖北武汉430030

出　　处：《中国肿瘤》2013年第7期554-557,共4页China Cancer

摘　　要：多形性胶质母细胞瘤（glioblastoma multiforme,GBM）是一类在形态学上具有异质性的原发性脑肿瘤,恶性程度极高,其标准治疗方法是手术＋术后放疗＋以替莫唑胺（temozolomide,TMZ）为基础的化疗。但GBM患者易对放疗产生抵抗以及对化疗耐药,该治疗方案的有效率有限,患者中位生存期约15个月。40%~50%GBM患者体内存在表皮生长因子受体（epidermal growth factor receptor,EGFR）的扩增和过表达。全文对EGFR表达与GBM放疗抵抗的相关机制作一综述。Glioblastoma multiforme（GBM） is an aggressive primary brain tumor with morphologically heterogeneous,characterized by resistance to standard treatment modalities including surgery,radiation therapy and temozolomide（TMZ）-based chemotherapy. Due to its occurrence of resistance to ionizing radiation（IR） and chemotherapy,response of this therapeutic modality is limited and the median survival is about 15 months. Approximately 40%~50% of patients with GBM are characterized by gene amplification and overexpression of the epidermal growth factor receptor（EGFR）. In this article,we discuss the EGFR signaling and the mechanism of resistance to radiation in patients with GBM.

关 键 词：多形性胶质母细胞瘤 EGFR 放疗 抵抗 

分 类 号：R739.41[医药卫生—肿瘤]